Kura Oncology Inc. (NASDAQ:KURA) shares fell 1.3% on Friday . The company traded as low as $4.91 and last traded at $5.33, with a volume of 3,307,284 shares. The stock had previously closed at $5.26.

A number of research firms recently weighed in on KURA. Zacks Investment Research raised Kura Oncology from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a report on Wednesday. Citigroup Inc. decreased their target price on Kura Oncology from $19.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, March 21st. Finally, Oppenheimer Holdings Inc. reissued an “outperform” rating and set a $16.00 target price on shares of Kura Oncology in a report on Tuesday, June 21st.

The stock’s market cap is $95.70 million. The company’s 50-day moving average price is $3.05 and its 200 day moving average price is $3.95.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, May 11th. The company reported ($0.36) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.01. On average, equities research analysts predict that Kura Oncology Inc. will post ($1.70) earnings per share for the current year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.